In the article “The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer” [Oncology. 2022, DOI: 10.1159/000526964] by Kasajima et al., the Tables 4 and 5 are missing in the final publication.
Table 4.
Analysis of factors potentially associated with progression-free survival
| Variable | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| hazard ratio (95% CI) | p value | hazard ratio (95% CI) | p value | |
| Sex | ||||
| Female | 1 (Ref.) | 0.50 | ||
| Male | 1.19 (0.71–2.00) | |||
| Age | ||||
| <75 years | 1 (Ref.) | 0.95 | ||
| ≥75 years | 1.02 (0.59–1.76) | |||
| ECOG performance status score | ||||
| 0–1 | 1 (Ref.) | 0.14 | ||
| 2–3 | 1.45 (0.88–2.39) | |||
| Histology | ||||
| Squamous | 1 (Ref.) | 0.70 | ||
| Non-squamous | 1.11 (0.65–1.92) | |||
| Clinical stage at diagnosis | ||||
| Recurrence | 1 (Ref.) | 0.08 | 1 (Ref.) | 0.015 |
| III/IV | 1.94 | 2.62 (1.20–5.73) | ||
| Mutation (EGFR/ALK) | ||||
| Wildtype/unknown | 1 (Ref.) | 0.12 | 1 (Ref.) | 0.058 |
| Mutant | 1.53 (0.90–2.59) | 1.74 (0.98–3.07) | ||
| Body mass index (kg/m2) | ||||
| Low (<20.4) | 1 (Ref.) | 0.042 | 1 (Ref.) | 0.031 |
| High (≥20.4) | 0.60 (0.36–0.98) | 0.56 (0.33–0.95) | ||
| GPS | ||||
| 0 | 1 (Ref.) | 0.01 | 1 (Ref.) | 0.012 |
| 1–2 | 1.91 (1.17–3.13) | 1.45 (1.09–1.94) | ||
| Regimen | ||||
| Pembrolizumab | 1 (Ref.) | 0.68 | ||
| Atezolizumab | 0.90 (0.54–1.50) | |||
| Smoking status | ||||
| Current or former | 1 (Ref.) | 0.73 | ||
| Never | 1.11 (0.61–2.00) | |||
| Tumor proportion score | ||||
| <50% | 1 (Ref.) | 0.29 | ||
| ≥50% | 0.76 (0.45–1.27) | |||
| Treatment line | ||||
| Second | 1 (Ref.) | 0.31 | ||
| Third or subsequent | 1.29 (0.79–2.08) | |||
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GPS, Glasgow prognostic score.
Table 5.
Analysis of factors potentially associated with overall survival
| Variable | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| hazard ratio (95% CI) | p value | hazard ratio (95% CI) | p value | |
| Sex | ||||
| Female | 1 (Ref.) | 0.16 | ||
| Male | 1.57 (0.84–2.92) | |||
| Age | ||||
| <75 years | 1 (Ref.) | 0.79 | ||
| ≥75 years | 0.92 (0.50–1.70) | |||
| ECOG performance status score | ||||
| 0–1 | 1 (Ref.) | 0.019 | 1 (Ref.) | 0.024 |
| 2–3 | 1.97 (1.12–3.48) | 1.99 (1.09–3.62) | ||
| Histology | ||||
| Squamous | 1 (Ref.) | 0.93 | ||
| Non-squamous | 1.03 (0.54–1.98) | |||
| Clinical stage at diagnosis | ||||
| Recurrence | 1 (Ref.) | 0.73 | ||
| III/IV | 1.15 (0.52–2.56) | |||
| Mutation (EGFR/ALK) | ||||
| Wildtype/unknown | 1 (Ref.) | 0.79 | ||
| Mutant | 1.09 (0.59–2.02) | |||
| Body mass index (kg/m2) | ||||
| Low (<20.4) | 1 (Ref.) | 0.017 | 1 (Ref.) | 0.055 |
| High (≥20.4) | 0.50 (0.28–0.88) | 0.56 (0.30–1.01) | ||
| GPS | ||||
| 0 | 1 (Ref.) | 0.001 | 1 (Ref.) | 0.017 |
| 1–2 | 2.66 (1.50–4.71) | 1.49 (1.07–2.05) | ||
| Regimen | ||||
| Pembrolizumab | 1 (Ref.) | 0.96 | ||
| Atezolizumab | 1.02 (0.65–1.84) | |||
| Smoking status | ||||
| Current or former smoker | 1 (Ref.) | 0.76 | ||
| Never smoker | 1.11 (0.56–2.23) | |||
| Tumor proportion score | ||||
| <50% | 1 (Ref.) | 0.068 | 1 (Ref.) | 0.068 |
| ≥50% | 0.56 (0.30–1.04) | 0.54 (0.28–1.05) | ||
| Treatment line | ||||
| Second | 1 (Ref.) | 0.18 | ||
| Third or more | 1.46 (0.83–2.57) | |||
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GPS, Glasgow prognostic score.